chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient is an otherwise healthy 17-year-old male who is presenting with recurrent symptoms of pericarditis in the setting of receiving the Pfizer vaccine 2 days ago.  He has uncomfortable substernal pain here, but is otherwise well-appearing with normal vital signs and a normal exam.  Bedside ultrasound showed what seem to be a trace effusion but grossly normal function.  EKG appears normal to me.  Inflammatory markers and troponin negative.  I reached out to cardiology given that he continues to have the symptoms and with his history.  They looked at his EKG and are questioning whether or not there is some interval PR depression.  They would like to get a formal echocardiogram. Tylenol and ibuprofen for pain.  Echocardiogram with trivial effusion, good function.  Patient was signed out to me as noted above.  Patient remained stable with good control of his pain.  Cardiology plans to follow-up with him as an outpatient on Monday or Tuesday at the beginning of next week.  They also advised that he have outpatient follow-up with rheumatology which they will help arrange.  The patient knows to return if he has increasing pain, shortness of breath or other change in symptoms.  Patient is discharged home with a prescription for naproxen to be taken twice daily over the next week.    Final Diagnosis  1. Pericarditis I31.9  Follow up January 2022: January 25.  He is being seen in follow-up for possible pericarditis.     Patient's medical history has been outlined in previous notes to your office.  He was last evaluated in our clinic on December 21 at which time an echocardiogram showed no pericardial effusion.  At that time the CRP was 0.06 and ESR 38.  Naprosyn and famotidine were discontinued at that time and colchicine 0.6 mg once a day was continued.     In the intervening time period Patient has remained symptom-free.  He reports no fever, chest pain, palpitations dizziness or syncope.     On physical examination patient appeared well.  His weight was 64.1 kg, height 175.5 cm, pulse rate 51, respiratory rate 18 and blood pressure 116/71 in the right arm.  The transcutaneous oxygen saturation was 100%.  Examination of his heart demonstrated a normal precordial activity single S1 and physiologically split S2.  There was no S3, S4 or ejection click.  There was no pericardial friction rub.  There was no murmur.  The breath sounds were clear.  There was no organomegaly.     An electrocardiogram demonstrated normal sinus rhythm and was within normal limits.  An echocardiogram showed normal cardiac anatomy and function.  Biventricular size and systolic function were normal.  The 4 cardiac valves had normal function.  There was no pericardial effusion.     Laboratory studies included CRP <0.06 and ESR 8.     Patient was judged to have a normal cardiac status.  I recommended that colchicine be discontinued at this time.  Followup was left to an as-needed basis.  Because of his brother's medical diagnosis I recommended that patient be evaluated by our Rheumatology Service.  The parents informed me that an appointment has been arranged.
This case was reported by a pharmacist and described the occurrence of Arthus-type reaction in a female subject aged between 50 and 59 years old who was vaccinated with BOOSTRIX. In 2012, "approximately two weeks ago", the subject received a dose of BOOSTRIX (unknown route, left arm). In 2012, less than one month after vaccination with BOOSTRIX, the subject experienced Arthus-type reaction, injection arm pain and shoulder pain in injection arm. The subject complained to the pharmacist of arm aching along with shoulder joint of left arm whenever her arm was used. The pharmacist asked how long an Arthus type reaction may last. The subject advised the pharmacist that she received the BOOSTRIX vaccine approximately two weeks ago at the physician's office and that whenever she used her arm it ached along with her shoulder joint. The pharmacist thought it was her left arm where the subject was administered the vaccine. The pharmacist did not know when the subject received her last Td vaccine. According the pharmacist, the subject called the physician's office and they informed her that this was a possible reaction to the vaccine. At the time of reporting the events were unresolved.
Father came to office 10/25/15 to notify that client had reactions that was not on VIS, given Tylenol and kept home from school that day. Called and spoke with Mother. Client complained of left upper back/top of shoulder pain radiating between shoulder blades. Developed cramp like pain in both thighs then suddenly dropped to ground like paralyzed. C/O back pain. Around 15 minutes later Mom assisted client up after sitting with her. Client said was painful and didn't want touch or movement and was hunched over c/o nausea and had low grade fever (felt warm) in the evening. No headache that night but did have headache in the morning. Mom states client has done gymnastics in the past and flips around at home. Mom states when left for work at 3:00 PM 10/25/16 client seemed fine. Did keep home from school that day (10/25) and was giving Ibuprofen. 10/31/16 f/u with Mom: Feels things are back to normal. Did not take for evaluation. Did have left side and back pain for a couple of days.
red / at the injection site; swollen / at the injection site; warm / at the injection site; itchy / at the injection site; painful /  at the injection site; Increased Neutrophils; This case was reported by a consumer via call center representative and described the occurrence of injection site erythema in a 71-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Concurrent medical conditions included cyclic neutropenia (being treated while vaccinated with Shingrix injection).   In September 2020, the patient received the 1st dose of Shingrix. On an unknown date, less than 2 weeks after receiving Shingrix, the patient experienced injection site erythema, injection site swelling, injection site warmth, injection site itching, injection site pain and neutrophils increased. On an unknown date, the outcome of the injection site erythema, injection site swelling, injection site warmth, injection site itching, injection site pain and neutrophils increased were recovered/resolved.   It was unknown if the reporter considered the injection site erythema, injection site swelling, injection site warmth, injection site itching, injection site pain and neutrophils increased to be related to Shingrix.  Additional details were reported as follows: The age at vaccination was not reported. The patient received the Shingrix injection while being treated for Cyclic Neutropenia. The patient received 1 st dose of Shingrix 2 weeks ago on right arm. The patient reported that she developed a red, swollen, warm itchy painful area at the injection site which lasted for 3 to 4 days. The patient stated that injection site still got itchy and was slightly pink. The patient  was in the process of determining if she had cyclical Neutropenia and was required to had blood drawn 3 times a week for 6 weeks. The patient stated 1 week later, neutrophils increased. The patient wondered if Shingrix had an effect on her blood work. The reported did not consent to follow up. All information was not available.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020193856:FU1 deleted
Initial report received from a non-healthcare professional on 08 October 2013. Two patients had received a dose of FLUZONE, (batch numbers- UH898AD and UH899AA, site of administration not reported) intramuscularly on an unspecified date of September 2013. The patient's medical history and concomitant medications were not reported. On an unspecified date, the patiens complained of soreness when it was being injected and for 2 days after. Laboratory details and corrective treatments were not reported. At the time of this report, the outcome was unknown. Documents held by sender: none. Follow up information received from the healthcare professional on 28 January 2014. The case was medically confirmed in follow up. The patient recovered on an unspecified date. The patient was vaccinated at private doctor office/hospital. Any other vaccination prior within 4 weeks prior to an unspecified date in September 2013 was reported as "NA".
tested postiive for Covid virus; tested postiive for Covid virus; First Dose, 15Jan2021, Second Dose 03Feb2021,; This is a spontaneous report from a contactable consumer (patient herself). A 40-years old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: solution for injection, lot number: EL1284, expiry date: unknown) on 15Jan2021 4:45PM (age at vaccination: 40 -years) as single dose and second dose (lot number: EL9263, expiry date: unknown) on 03Feb2021 9:15AM (age at vaccination: 40 -years) via unspecified route of administration in left arm as single dose for covid-19 immunisation. Vaccination facility type was hospital. Patient's medical history and concomitant medications were not reported. Patient was diagnosed with Covid yesterday 20Jul2021, and she was trying to find a way to report the breakthrough COVID diagnosis, had not seen anywhere on the website that they are tracking this information, could only find that they have tracked it through the end of Apr2021. She wanted to know if Pfizer was tracking this information. Patient had physician office visit due to adverse event. She went to respiratory clinic yesterday, doctor had her regen-cov infusion today for treatment, 21Jul2021. Prior Vaccinations (within 4 weeks) no other vaccinations within four weeks prior to the first administration date of the suspect vaccine was given. Patient was on the phone with one of their colleague and was reporting that she had the Pfizer vaccine in January and February but yesterday was diagnosed with COVID-19. So, she was reporting the breakthrough and had just about finished the report, the voluntary report but they were unfortunately disconnected. So, she doesnt know what else she needs to do to answer remaining questions but just wanted to complete that form. The outcome of event was not recovered, when reported.   Follow-Up (26Jul2021): Follow-up attempts are completed. No further information is expected.
fever; headache; chills; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (fever), HEADACHE (headache) and CHILLS (chills) in an adult female patient who received mRNA-1273 (Spikevax) for COVID-19 vaccination.     Concurrent medical conditions included Egg allergy (she was concerned the dose had eggs in it.).    On an unknown date, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced PYREXIA (fever), HEADACHE (headache) and CHILLS (chills). At the time of the report, PYREXIA (fever), HEADACHE (headache) and CHILLS (chills) outcome was unknown.        mRNA-1273 (Spikevax) (Unknown) dosing remained unchanged.       Concomitant medications was not provided by the reporter.  It was reported for the first couple of shots she had just mild reactions fever, headache, chills. Treatment information was not provided.   This case was linked to MOD-2022-533282, MOD-2022-533292 (Patient Link).
Tested positive COVID-19 on October 21, 2021, at my doctor's office. Symptoms began October 19th congestion, cough, headache, fatigue, nausea, sore throat and a fever 101.1. Went to urgent care, they directed me to ER, November 1, 2021, received steroid and few other IV medicines, also developed sinus infection and eye infection and amoxicillin for sinus infection and Polymyxin B Sulfate eye drops.
Nine days after first shot, small red mark around injection site, no pain or itching.  Changed shape a bit, then went  away a few days after.
allergic to peanuts; This spontaneous report was received from a consumer, physician and via a company representative and refers to a female patient of unknown age.  The patient's concurrent conditions were not reported. Concomitant therapies were not reported.  On an unknown date, the patient was vaccinated with quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) intramuscular injection,administered for prophylaxis (strength, dose description, lot #, expiry date, and route of administration were not provided).  The reporter stated that the patient became severely allergic to peanuts (food allergy) six months after receiving the vaccine. Their mother had indicated that her daughter had never had these allergies before receiving quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL).  The causal relationship between food allergy and quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) was unknown.  This is one of two reports received from the same source.; Sender's Comments:  US-009507513-2210USA008546:
Information has been received from a physician via company representative referring to a 14 year old female patient who was not pregnant. Medical history and concurrent condition were not reported. On an unspecified date the patient was vaccinated with the first dose of GARDASIL 9 (0.5 ml, route and lot# not reported) and on 09-OCT-2015 the patient was vaccinated with the second dosage (0.5 ml, intramuscular, lot# not reported). It was reported that the patient had adverse reaction to GARDASIL 9. On 09-OCt-2015, the patient developed site injection distress (entire arm). The patient went to Emergency Room and had treatment on the same day. The patient was hospitalized on an unspecified date. The vaccine was continued. At the time of reporting, the patient was recovering from the event. Additional information is not expected as there was no physician's contact information.
First Day:  At first: Tense, Restless;  Later off and on: Headache, Chills, Fever 98.2*, Hands Numb and Cold Took Tylenol with Codeine for Headache Second Day: Off and on: Headache, Chills, Fever <100*,  Hands Numb and Cold Took Tylenol with Codeine for Headache Third Day:  Off and on: Headache, Chills, Fever 100.2* Took Tylenol with Codeine for Headache
He received the first dose of COVID vaccine on 3/6/21 and second dose on 3/27/22. He presented to the ED at Hospital with chief complain of fever, nausea, cough, and congestion on 5/20/22. Apparently his wife was tested COVID positive 9 days prior to this visitation. His temp was 103.1 and COVID test resulted in positive. Subsequently he was admitted for medical management. He received two doses of Remdesivir, steroids, Azithromycin, and Ceftriaxone. He was medically stable, able to wean off supplemental oxygen, and discharged home on 5/23/22.
Became sick/Positive with Covid-19 after being fully vaccinated; Became sick/Positive with Covid-19 after being fully vaccinated; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  A 6-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection), administered in arm right, administration date 03Dec2021 (Lot number: FL0007) at the age of 6 years as dose 2, single and administered in arm right, administration date 10Nov2021 (Lot number: FK5127) as dose 1, single for COVID-19 immunisation. The patient had no relevant medical history and no known allergies. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine and was not diagnosed with COVID-19 prior to vaccination. There were no concomitant medications. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 03Jan2022, outcome "recovering" and all described as "Became sick/Positive with Covid-19 after being fully vaccinated". The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (03Jan2022) positive. Therapeutic measures were not taken as a result of vaccination failure, COVID-19.
Tiredness, fell asleep almost immediately afterwards Vaccination was given. He woke up with Ophthalmic Migraines, dizziness followed by his eyes sight spontaneously going completely black.
I got the Pfizer covid shots and booster shot, so I was really surprised I get it (the covid infection; I got the Pfizer covid shots and booster shot, so I was really surprised I get it (the covid infection; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team, Program ID. The reporter is the patient.  A female patient received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "I got the Pfizer covid shots and booster shot, so I was really surprised I get it (the covid infection". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: I took a home test and it showed it was positive, then my doctor did a test and told me its positive; Positive, notes: I took a home test and it showed it was positive, then my doctor did a test and told me its positive. Therapeutic measures were taken as a result of drug ineffective, covid-19. Course of events: She got the Pfizer covid shots and booster shot, so she was really surprised she even got this (the covid infection, she got the shot, she has worn her mask, she never had a problem like this even as a result after receiving the booster shot. She was fine 1 minute and 15 minutes later she felt like she was hit by a truck, that's how bad and fast it hit, this was not a gradual getting sick, the chills and pain, headache, nausea, fever. She took a home test and it showed it was positive, then her doctor did a test and told her it was positive and started her on Paxlovid, apparently from the day you start you have 2 days to start it. The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Mfg: GLAXO SMITH KLINE.  GROUP P5387 Redness, rash, sore upper left arm and still neck on right side.  Tired.  Pharmacist recommended  Benadryl and to contact VAERS.
Patient sneezed more than 20 times, became flushed, hot, diaphoretic.
PATIENT REPORTS HAVING SWELLING AT THE SITE OF INJECTION ALONG WITH TIGHTNESS/SWELLING IN THE THROAT AND TROUBLE BREATHING WHEN LAYING DOWN AFTER HAVING INJECTION EARLIER IN THE DAY.
Expired vaccines was administered to patient just today.  Patient has not yet reported any adverse events.   We will contact manufacturer this week to verify what our next course of action should be.
Mom states, 6 hours, post vax, child developed a temperature of 103F. Seen in ER and treated with Tylenol. Episode resolved in 4 hours. ER MD advised that temperature was most likely due to immunizations, since no symptoms of infection were present.
Patient reported on 11/29/21 that when the vaccine was administered on October 5th in her left arm it felt like tons of hornets and experienced extreme pain.  pt reported getting a steroid about 4 weeks after.  Pt reported that the pain was not resolving still. Pt encouraged to see specialist again.
Fainted after shot was administered.  Patient was not in any distress before, directectly after or the next day.
Immunized with smallpox vaccine 26 AUG 2003.  Developed fever, malaise, fatigue, soreness, vesicular lesions and erythema around innoculation site on 03 SEP 2003.  Developed progressive vesicular lesions on 06 SEP 2003 on face, scalp, anterior chest above nipple line, on back above scapulae, symmetric in distribution. No ocular or mucosal lesions.  Developed one vesicular lesion on posterior aspect of Left thigh on 07 SEP 2003.
Post vaccination the pt developed a local injection site reaction described as redness and pain. The pt sought unspecified medical attention. No further information is available.
receiving 2nd dose with less than a 2 month interval; This case was reported by a nurse via call center representative and described the occurrence of drug dose administration interval too short in a 51-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Concomitant products included Herpes zoster (Shingrix).   On 10th December 2020, the patient received the 2nd dose of Shingrix. On 10th December 2020, unknown after receiving Shingrix, the patient experienced drug dose administration interval too short. On an unknown date, the outcome of the drug dose administration interval too short was unknown.  Additional details were provided as follows: The patient never received a valid 2nd dose of Shingrix, received 2nd dose with less than a 2-months interval, earlier than the recommended schedule, which led to shortening of vaccination schedule.  No additional doses were given.  The reporter consented to follow up.; Sender's Comments:  US-GLAXOSMITHKLINE-US2022042575:FU1 - duplicate - deleted
PARENT SAID THIS WAS HER THIRD DOSE.  WE VACCINATED AND WHEN WE WENT TO REPORT ON SYSTEM, PATIENT ALREADY HAD PRIMARY DOSE AND BOOSTER.   SO SHE GOT A 2ND BOOSTER (4TH DOSE).  WE SHOULD HAVE LOOKED ON SYSTEM BEFORE VACCINATING.  SHE DID NOT HAVE ANY SYMPTOMS.
Child received DTaP, Hib (#4) Left thigh on 8-16. On AM of 8/17. Mom noticed red area around site of injection.  Child seen in office 8/17. No sxs other than 4-6 cm area of erythema. A febrile, well-appearing.
Pt devel fever 103.5 occurred 1 day p/vax; 104.2 a few hrs later 1 day p/immun;
Narrative:  Patient had nausea and vomiting followed by syncope after getting home following vaccine. Patient called office and was advised to go to the emergency department. Patient went to non-agency ED, had a CT of abdomen and then returned home.
Within two days, fever (low-grade), muscle aches, extremely sore throat, sinus congestion, fatigue, inability to work or function at home. Congestion, fatigue continue as of today (10/29/03).
This case was reported by a physician via sales rep and described the occurrence of fever in a child patient who received PEDIARIX. On an unknown date, the patient received the 1st dose of PEDIARIX (intramuscular). On an unknown date, an unknown time after receiving PEDIARIX, the patient experienced fever. On an unknown date, the outcome of the fever was recovered/resolved. The reporter considered the fever to be almost certainly related to PEDIRIX. Additional details provided were as follows: The patient experienced high fever. Limited information was provided by the sales representative from the physician. This was 1 of the 4 cases reported by the same reporter (US2016038398, US2016038401 and US 20160384012).
A few minutes after the shot, the patient said he was not feeling well,  and told the pharmacist he was about to pass out and felt very dizzy. He was extremely pale and sweating profusely all over. We took his blood pressure and it was about 94/50. His heart rate was 50. We got the patient water and continued to monitor him and he improved.
Swelling, redness, tenderness, pain left axillary lymph nodes and spread to entire left pectoralis and upper left chest area. Developed initially 2 days after vaccine, progressed for 4 days.
This spontaneous report as received from a 48 years old female consumer as part of marketing research study reporting on herself. The patient's pertinent medical history or concurrent conditions were not provided. On an unknown date the patient was vaccinated with a dose of PNEUMOVAX 23 (manufacturer unknown) (route, dose, lot# and expiration date were not reported). On an unknown date the patient experienced malaise reported as "usually got sick". The outcome of the malaise was unknown. Additional information has been requested.
Patient received Pfizer Pediatric 5-11 vaccine of 0.2 MLs instead of the Pfizer adult vaccine.  No adverse affects reported. Per CDC Guidelines patient to return as soon as possible for full dose of adult vaccine. Called patient to return to the clinic for the Pfizer adult dose. Patient to return on 11/23.